| 前收盘价格 | 2.51 |
| 收盘价格 | 2.54 |
| 成交量 | 3,946,345 |
| 平均成交量 (3个月) | 3,656,100 |
| 市值 | 858,335,424 |
| 价格/销量 (P/S) | 53.70 |
| 股市价格/股市净资产 (P/B) | 1.60 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2025 - 8 Aug 2025 |
| 营业利益率 (TTM) | -1,913.23% |
| 稀释每股收益 (EPS TTM) | -2.20 |
| 总债务/股东权益 (D/E MRQ) | 2.72% |
| 流动比率 (MRQ) | 9.01 |
| 营业现金流 (OCF TTM) | -157.34 M |
| 杠杆自由现金流 (LFCF TTM) | -64.76 M |
| 资产报酬率 (ROA TTM) | -23.33% |
| 股东权益报酬率 (ROE TTM) | -119.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Nuvation Bio Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | 3.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.20 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 19.14% |
| 机构持股比例 | 61.81% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2025 | 25,954,439 |
| Omega Fund Management, Llc | 31 Mar 2025 | 13,072,340 |
| Laurion Capital Management Lp | 31 Mar 2025 | 9,871,077 |
| Mpm Bioimpact Llc | 31 Mar 2025 | 4,652,243 |
| Tang Capital Management Llc | 31 Mar 2025 | 3,900,000 |
| Aisling Capital Management Lp | 31 Mar 2025 | 2,541,009 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 6.00 (RBC Capital, 137.15%) | 购买 |
| 6.00 (JMP Securities, 137.15%) | 购买 | |
| 中 | 6.00 (137.15%) | |
| 低 | 5.00 (Wedbush, 97.63%) | 购买 |
| 平均值 | 5.67 (124.11%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 1.96 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JMP Securities | 25 Jun 2025 | 6.00 (137.15%) | 购买 | 1.97 |
| 02 Jun 2025 | 6.00 (137.15%) | 购买 | 2.34 | |
| RBC Capital | 17 Jun 2025 | 6.00 (137.15%) | 购买 | 1.71 |
| Wedbush | 11 Jun 2025 | 5.00 (97.63%) | 购买 | 2.20 |
| 16 May 2025 | 5.00 (97.63%) | 购买 | 2.26 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HUNG DAVID | 1.86 | - | 500,000 | 930,000 |
| MARKEL STACY | 1.79 | - | 10,000 | 17,900 |
| SAUVAGE PHILIPPE | 1.79 | - | 7,300 | 12,978 |
| SJOGREN COLLEEN | 1.86 | - | 50,000 | 93,000 |
| WENTWORTH KERRY | 1.86 | - | 50,000 | 93,000 |
| 累积净数量 | 617,300 | |||
| 累积净值 ($) | 1,146,878 | |||
| 累积平均购买 ($) | 1.82 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MARKEL STACY | 职员 | 18 Jun 2025 | 买 (+) | 10,000 | 1.79 | 17,900 |
| SAUVAGE PHILIPPE | 职员 | 17 Jun 2025 | 买 (+) | 4,000 | 1.71 | 6,840 |
| HUNG DAVID | 职员 | 16 Jun 2025 | 买 (+) | 500,000 | 1.86 | 930,000 |
| WENTWORTH KERRY | 职员 | 16 Jun 2025 | 买 (+) | 50,000 | 1.86 | 93,000 |
| SAUVAGE PHILIPPE | 职员 | 16 Jun 2025 | 买 (+) | 3,300 | 1.86 | 6,138 |
| SJOGREN COLLEEN | 职员 | 16 Jun 2025 | 买 (+) | 50,000 | 1.86 | 93,000 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合